El linfocito: protagonista en la nueva era de los biológicos

Jullien, 2004, T-cell modulation for the treatment of chronic plaque psoriasis with efalizumab (Raptiva(tm)): Mechanism of action, Dermatology, 208, 297, 10.1159/000077660 Prinz, 2003, The role of T cells in psoriasis, J Eur Acad Dermatol Venereol, 17, 257, 10.1046/j.1468-3083.2003.00720.x Vugmeyster, 2004, Efalizumab (anti-CD11a) induced increase in peripheral blood leukocytes in psoriasis patients is preferentially mediated by altered trafficking of memory CD8+ cells into lesional skin, Clin Immunol, 113, 38, 10.1016/j.clim.2004.06.001 Schleyer, 2005, Novel pharmacological approaches in the treatment of psoriasis, J Eur Acad Dermatol Venereol, 19, 1, 10.1111/j.1468-3083.2004.01070.x Barry, 2004, Novel biologic therapies for psoriasis, Expert Opin Biol Ther, 4, 975, 10.1517/14712598.4.6.975 Menter, 2004 Ficha técnica de Efalizumab, febrero 2007. Cather, 2003, Modulating T cell responses for the treatment of psoriasis: a focus on efalizumab, Expert Opin Biol Ther, 3, 361, 10.1517/14712598.3.2.361 Lee, 2003, The immunological synapse balances T cell receptor signaling and degradation, Science, 302, 1218, 10.1126/science.1086507 Bradley, 1996, Lymphocyte migration into tissue: the paradigm derived from CD4 subsets, Curr Opin Immunol, 8, 312, 10.1016/S0952-7915(96)80118-X Gottlieb, 2000, Effects of administration of a single dose of a humanized monoclonal antibody to CD11a on the immunobiology and clinical activity of psoriasis, J Am Acad Dermatol, 42, 428, 10.1016/S0190-9622(00)90214-7 Gottlieb, 2002, Psoriasis as a model for T-cellmediated disease: Immunobiologic and clinical effects of treatment with multiple doses of efalizumab, an anti-CD11a antibody, Arch Dermatol, 138, 591, 10.1001/archderm.138.5.591 Gottlieb, 2003, Subcutaneously administered efalizumab (anti-CD11a) improves signs and symptoms of moderate to severe plaque psoriasis, J Cutan Med Surg, 7, 198, 10.1007/s10227-002-0118-1 Papp, 2001, The treatment of moderate to severe psoriasis with a new anti-CD11a monoclonal antibody, J Am Acad Dermatol, 45, 665, 10.1067/mjd.2001.117850 Werther, 1996, Humanization of an anti-lymphocyte function-associated antigen (LFA)-1 monoclonal antibody and reengineering of the humanized antibody for binding to rhesus LFA-1, J Immunol, 157, 4986, 10.4049/jimmunol.157.11.4986 Dedrick, 2002, Anti-adhesion antibodies: efalizumab, a humanized anti-CD11a monoclonal antibody, Transpl Immunol, 9, 181, 10.1016/S0966-3274(02)00029-1 Leonardi CL, Gordon KB, Walicke PA, Li N, Joshi A, Menter A. The efficacy, safety, pharmacokinetics, and pharmacodynamics of efalizumab in patients with plaque psoriasis: results of a phase III trial. Poster presented at: International Investigative Dermatology. Annual Meeting; April 30-May 4, 2003. Miami, Fla. Poster 1246. Dedrick RL, Bauer R, Bohmann D. Pharmacokinetics and pharmacodynamics of subcutaneously administered efalizumab (anti-CD11a) in psoriasis subjects. Poster presented at: 59th AnnualMeeting of the American Academy of Dermatology; March 2-7, 2001; Washington, DC. Abstract and poster 505. Kuebler, 2003, No evidence of long term treatment effects on lymphocytes are observed after treatment with efalizumab [poster PII-91], Clin Pharmacol Ther, 73, P53, 10.1016/S0009-9236(03)90553-4 Joshi, 2006, An overview of the pharmacokinetics and pharmacodynamics of efalizumab: a monoclonal antibody approved for use in psoriasis, J Clin Pharmacol, 46, 10, 10.1177/0091270005283282